Source comparison
Thymosin Alpha-1 Support Long COVID Research: Comparison
Thymosin Alpha-1 T-cell maturation agonist; enhances thymic output and regulatory T-cell function Phase II RCT data; observational cohorts show 34–40% IL-6 reduction 1.6mg subcutaneous injection twice weekly for 8–12 weeks Mild injection-site reactions (10–15%
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- T-cell maturation agonist; enhances thymic output and regulatory T-cell function
- Phase II RCT data; observational cohorts show 34–40% IL-6 reduction
- 1.6mg subcutaneous injection twice weekly for 8–12 weeks
- Mild injection-site reactions (10–15%); no systemic toxicity reported
- Most promising immune-modulating peptide under active investigation; targets root dysregulation rather than symptoms
- Low-Dose Naltrexone
- Opioid receptor antagonist; proposed to reduce microglial activation
- Retrospective case series only; no RCT data in Long COVID
- 1.5–4.5mg oral daily
- Vivid dreams, transient insomnia (20–30%); generally well-tolerated
- Widely prescribed off-label but lacks mechanistic validation in post-viral syndromes
- Corticosteroids
- Broad anti-inflammatory; suppresses cytokine transcription
- Not recommended. Early use associated with prolonged viral shedding; no benefit in post-acute phase
- N/A in Long COVID treatment
- Immunosuppression, hyperglycemia, adrenal suppression
- Contraindicated except in specific autoimmune complications (e.g., myocarditis)
- IVIG (Intravenous Immunoglobulin)
- Provides passive antibodies; modulates B-cell activity
- Small case series (n=18); mixed results; 40% responders vs 60% non-responders
- 2g/kg divided over 2–5 days monthly
- Infusion reactions, thrombotic risk, expensive ($5,000–15,000/dose)
- Reserved for severe autoimmune-dominant Long COVID; not first-line due to cost and limited evidence
- Exercise Rehabilitation
- Gradual reconditioning; proposed to reset autonomic tone
- Strong evidence for symptom management but does not reverse immune dysfunction
- Individualized graded protocols
- Post-exertional malaise in 30–50% if improperly dosed
- Essential supportive therapy but insufficient as monotherapy for immune-driven cases